Nanopharmaceuticals Market, By Drug Carrier (Liposomes, Polymer, Nanocrystals, Inorganic, Protein, and Others), By Application (Oncology, Neurology, Anti-inflammatory/Immunology, Anti-infective, Cardiovascular/Physiology, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Trends, Analysis and Forecast till 2034.

Report Code: PMI430720 | Publish Date: February 2024 | No. of Pages: 170

Global Nanopharmaceuticals Market Overview

Nanopharmaceuticals market was valued at US$ 26 Billion in 2024 and is projected to grow at a CAGR of 6.80% to reach US$ 47.3 Billion by 2034.

Nanopharmaceuticals is defined as nanotechnology-based pharmaceuticals. Nanopharmaceuticals are particles in the size range 10 to 1,000 nanometers of specific matter used in the production of drugs. As a result of shape and composition, the medicines have several advantages to offer over the normal medicines. The technology is still in evolution stages and has potential to bring advancement not only in therapeutics but also in detecting diseases and targets. Additionally, cost-effectiveness is one factor that is making it popular.

Global Nanopharmaceuticals Market Dynamics

Growth in the prevalence of chronic diseases such as infectious diseases, cancer, and cardiovascular diseases, is one of the main driver propelling the global nanopharmaceuticals market. Prominent players are investing on large scale in the nanopharmaceuticals market in order to launch improved medicines in the target market. The advancements in the nanopharmaceuticals are probably to address therapeutics for critical diseases, which are yet to be explored. For example, In August 2017, Jazz Pharmaceuticals, a key player of nano-pharmaceuticals market received FDA approval for Vyxeos. Vyxeos is primarily used for the treatment of acute myeloid leukemia. Registering the developments and pace of research underway for nanopharmaceuticals, global nano-pharmaceuticals market is estimated to rise at a significant pace in the coming years.

However, factors such as toxicity issues, less solubility of nanopharmaceuticals, and its functioning need to be addressed on a wider scale. If not, these factors might limit the growth of the global nanopharmaceutical market over the forecast period.

Access Crucial Insights at a Fraction of the Cost | Request Your Discount

Global Nanopharmaceuticals Market Segmentation

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

The global Nanopharmaceuticals market is segmented based on drug carrier, application, distribution channel, and region.

On the basis of drug carrier, the global nanopharmaceuticals market is segmented into liposomes, polymer, nanocrystals, inorganic, protein, and others. On the basis of application, the target market is classified into oncology, neurology, anti-inflammatory/immunology, anti-infective, cardiovascular/physiology, and others. On the basis of distribution channel, the target market is classified into hospital pharmacies, retail pharmacies, and online pharmacies.

Regional Insights:

Disclaimer: This data is only a representation. Actual data may vary and will be available in the report.

On region the global nanopharmaceuticals market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to register highest share of the global nanomedicine market and maintain its position over the forecast period, owing to growing presence of patented nanomedicine products. Additionally, rapid acceptance of nanomedicine and the availability of advanced healthcare infrastructure and are some of the other major factors that are projected to improve the growth of the nanopharmaceuticals market in North America in the future. Moreover, Asia Pacific is anticipated to register substantial growth, owing to growing contribution from India, China, and Indonesia. Further, the growing investments in research and development activities for the introduction of advanced therapies and drugs are estimated to speed up the growth of this region over the forecast period.

Reduce costs by up to 30% with a custom report tailored to your specific needs | Request Customized Report

Attribute

Details

Base year for estimation

2024

Forecast period

2024 – 2034

Market representation

Revenue in USD Million & CAGR from 2024 – 2034

Market Segmentation

By Drug Carrier - Liposomes, Polymer, Nanocrystals, Inorganic, Protein, and Others

By Application- Oncology, Neurology, Anti-inflammatory/Immunology, Anti-infective, Cardiovascular/Physiology, and Others

By Distribution Channel - Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies

Regional scope

North America - U.S., Canada

Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe

Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific

Latin America - Brazil, Mexico, Argentina, Rest of Latin America

Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa

Report coverage

Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest application trends and opportunities in each of the sub-segments from 2019 to 2029. For the purpose of this study, has segmented the global nanopharmaceuticals market report based on drug carrier, application, distribution channel, and region.

Nanopharmaceuticals Market, By Drug Carrier:

  • Liposomes
  • Polymer
  • Nanocrystals
  • Inorganic
  • Protein
  • Others

Nanopharmaceuticals Market, By Application:

  • Oncology
  • Neurology
  • Anti-inflammatory/Immunology
  • Anti-infective
  • Cardiovascular/Physiology
  • Others

 Nanopharmaceuticals Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Nanopharmaceuticals Market, By Region:

  • North America
    • U.S.
    • Canada
  • Europe
    • Rest of Europe
    • Italy
    • Russia
    • France
    • UK
    • Germany
  • Asia Pacific
    • Rest of Asia Pacific
    • South Korea
    • Japan
    • India
    • China
  • Latin America
    • Rest of Latin America
    • Mexico
    • Brazil
  • Middle East & Africa
    • Rest of Middle East & Africa
    • South Africa
    • Israel
    • GCC

Global Nanopharmaceuticals Market Key Players

The key players operating the global nanopharmaceuticals market includes Teva Pharmaceuticals Industries Limited, AbbVie Inc., JOHNSON & JOHNSON, Novartis AG, Hoffmann-La Roche AG, Shire Plc., Pfizer Inc., Merck & Co., Sanofi S.A., AMAG Pharmaceuticals, and Amgen Inc. Prominent players are bringing several developments and strategies in the market to increase foothold in the market. Prominent players are expanding their reign by merging, acquisitions, and collaborations. For instance on April 2020, Merck announced that the Phase 3 KEYNOTE-177 trial evaluating first-line treatment of KEYTRUDA, Merck’s anti-PD-1 therapy, in patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) unrespectable or metastatic colorectal cancer met one of its dual primary endpoints of progression-free survival (PFS).

Global Nanopharmaceuticals Market Company Profile

  • Teva Pharmaceuticals Industries Limited
    • Company Overview
    • Product Drug Carrier Portfolio
    • Key Highlights
    • Financial PerRaw Materialance
    • Business Strategies
  • AbbVie Inc.
  • JOHNSON & JOHNSON
  • Novartis AG
  • Hoffmann-La Roche AG
  • Shire Plc.
  • Pfizer Inc.
  • Merck & Co.
  • Sanofi S.A.
  • AMAG Pharmaceuticals
  • Amgen Inc.

“*” marked represents similar segmentation in other categories in the respective section

Global Nanopharmaceuticals Market Table of Contents

  1. Research Objective and Assumption
    • Preface
    • Research Objectives
    • Study Scope
    • Years Considered for the study
    • Assumptions
    • Abbreviations
  2. Research Methodology
    • Research data
    • Primary Data
      • Primary Interviews
      • Primary Breakdown
      • Key data from Primary Sources
      • Key Thickness Insights
    • Secondary Data
      • Major Secondary Sources
      • Secondary Sources
    • Market Estimation
    • Top-Down Approach
      • Approach for estimating Market Share by Top-Down Analysis (Supply Side)
    • Bottom-Up Approach
      • Approach for estimating market share by Bottom-up Analysis (Demand Side)
    • Market Breakdown and Data Triangulation
    • Research Assumptions
  3. Market Purview
    • Executive Summary
    • Key Findings—Global Outlook for Nanopharmaceuticals Strategies
      • Key Questions this Study will Answer
      • Market Snippet, By Drug Carrier
      • Market Snippet, By Application
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Opportunity Map Analysis
    • Executive Summary—3 Big Predictions
  4. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
      • Market Trends
    • DR Impact Analysis
    • PEST Analysis
    • Porter’s Five Forces Analysis
    • Opportunity Orbit
    • Market Investment Feasibility Index
    • Macroeconomic Factor Analysis
  5. Global Nanopharmaceuticals Market, By Drug Carrier, 2020 – 2029, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2029
      • Y-o-Y Growth Analysis (%), 2020 – 2029
      • Segment Trends
    • Liposomes
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2029
    • Polymer
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2029
    • Nanocrystals
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2029
    • Inorganic
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2029
    • Proteins
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2029
    • Others
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2029
  6. Global Nanopharmaceuticals Market, By Application, 2020 – 2029, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2029
      • Y-o-Y Growth Analysis (%), 2020 – 2029
      • Segment Trends
    • Oncology
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2029
    • Neurology
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2029
    • Anti-inflammatory/Immunology
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2029
    • Anti-infective, Cardiovascular/Physiology
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2029
    • Others
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2029
  7. Global Nanopharmaceuticals Market, By Distribution Channel, 2020 – 2029, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2029
      • Y-o-Y Growth Analysis (%), 2020 – 2029
      • Segment Trends
    • Hospital Pharmacies
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2029
    • Retail Pharmacies
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2029
    • Online Pharmacies
      • Overview
      • Market Size and Forecast (US$ Mn), and Y-o-Y Growth (%), 2020 – 2029
  8. Global Nanopharmaceuticals Market, By Region, 2020 – 2029, (US$ Mn)
    • Overview
      • Market Value and Forecast (US$ Mn), and Share Analysis (%), 2020 – 2029
      • Y-o-Y Growth Analysis (%), 2020 – 2029
      • Regional Trends
    • North America
      • Market Size and Forecast (US$ Mn), By Drug Carrier, 2020 – 2029
      • Market Size and Forecast (US$ Mn), By Application, 2020 – 2029
      • Market Size and Forecast (US$ Mn), By Distribution Channel, 2020 – 2029
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2029
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast (US$ Mn), By Drug Carrier, 2020 – 2029
      • Market Size and Forecast (US$ Mn), By Application, 2020 – 2029
      • Market Size and Forecast (US$ Mn), By Distribution Channel, 2020 – 2029
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2029
        • Germany
        • UK
        • France
        • Russia
        • Italy
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast (US$ Mn), By Drug Carrier, 2020 – 2029
      • Market Size and Forecast (US$ Mn), By Application, 2020 – 2029
      • Market Size and Forecast (US$ Mn), By Distribution Channel, 2020 – 2029
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2029
        • China
        • India
        • Japan
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast (US$ Mn), By Drug Carrier, 2020 – 2029
      • Market Size and Forecast (US$ Mn), By Application, 2020 – 2029
      • Market Size and Forecast (US$ Mn), By Distribution Channel, 2020 – 2029
      • Market Size  and Forecast (US$ Mn), By Country, 2020 – 2029
        • Brazil
        • Mexico
        • Rest of Latin America
    • Middle East & Africa
      • Market Size and Forecast (US$ Mn), By Drug Carrier, 2020 – 2029
      • Market Size and Forecast (US$ Mn), By Application, 2020 – 2029
      • Market Size and Forecast (US$ Mn), By Distribution Channel, 2020 – 2029
      • Market Size and Forecast (US$ Mn), By Country, 2020 – 2029
        • GCC
        • Israel
        • South Africa
        • Rest of Middle East
  9. Competitive Landscape
    • Heat Map Analysis
    • Market Presence and Specificity Analysis
  10. Company Profiles
      • Teva Pharmaceuticals Industries Limited
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Overview
        • Business Strategies
      • AbbVie Inc.
      • JOHNSON & JOHNSON
      • Novartis AG
      • Hoffmann-La Roche AG
      • Shire Plc.
      • Pfizer Inc.
      • Merck & Co.
      • Sanofi S.A.
      • AMAG Pharmaceuticals
      • Amgen Inc.
  11. The Last Word
    • Future Impact
    • About Us
    • Contact

FAQs

The global nanopharmaceuticals market is segmented based on drug carrier, application, distribution channel, and region.

Growth in the prevalence of chronic diseases such as infectious diseases, cancer, and cardiovascular diseases, is one of the main drivers propelling the global nanopharmaceuticals market.

North America is expected to register the highest share of the global nanomedicine market and maintain its position over the forecast period, owing to the growing presence of patented nanomedicine products. Additionally, rapid acceptance of nanomedicine and the availability of advanced healthcare infrastructure and are some of the other major factors that are projected to improve the growth of the nanopharmaceuticals market in North America in the future.

Prominent players are bringing several developments and strategies in the market to increase foothold in the market. Prominent players are expanding their reign by merging, acquisitions, and collaborations. For instance, on April 2020, Merck announced that the Phase 3 KEYNOTE-177 trial evaluating first-line treatment of KEYTRUDA, Merck’s anti-PD-1 therapy, in patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) unresectable or metastatic colorectal cancer met one of its dual primary endpoints of progression-free survival (PFS).